Regulating opioid prescribing through prescription monitoring programs: Balancing drug diversion and treatment of pain

Pain Medicine

Volumn 5, Issue 3, 2004, Pages 309-324

  Fishman, Scott M ^a   Papazian, Jennifer S ^a   Gonzalez, Susana ^a   Riches, Paul S ^b   Gilson, Aaron ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b California Board of Pharmacy   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Abuse; Diversion; Monitoring programs; Opioid; Prescription; Security paper; Tamper resistant; Triplicates

Indexed keywords

AMPHETAMINE; ANABOLIC AGENT; ANTIDIARRHEAL AGENT; ANTITUSSIVE AGENT; ATROPINE PLUS DIPHENOXYLATE; BENZODIAZEPINE; BENZPHETAMINE; CANNABIS; CHLORAL HYDRATE; COCAINE; CODEINE; DEXTROPROPOXYPHENE; DIAMORPHINE; DRONABINOL; FENFLURAMINE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; LYSERGIC ACID; MEPROBAMATE; MESCALINE; METHADONE; METHAQUALONE; METHYLPHENIDATE; METHYPRYLON; MORPHINE; NARCOTIC AGENT; OPIATE; OXYCODONE; PHENOBARBITAL; UNINDEXED DRUG;

ANALGESIA; DRUG ABUSE; DRUG MONITORING; GOVERNMENT; HEALTH PROGRAM; HUMAN; PAIN; PHYSICIAN; POLICY; PRESCRIPTION; PUBLIC HEALTH; REVIEW; TECHNOLOGY; TREATMENT FAILURE; UNITED STATES;

ANALGESICS, OPIOID; CALIFORNIA; DRUG AND NARCOTIC CONTROL; DRUG UTILIZATION REVIEW; GOVERNMENT AGENCIES; GOVERNMENT PROGRAMS; GOVERNMENT REGULATION; HUMANS; LEGISLATION, DRUG; LEGISLATION, PHARMACY; PAIN; PRESCRIPTIONS, DRUG; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 5644277890     PISSN: 15262375     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2004.04049.x     Document Type: Review

References (91)

1. Heit HA. The truth about pain management: The difference between a pain patient and an addicted patient. Eur J Pain 2001;5(suppl A):27-9.
2. Wolfe SM. A Public Citizen Health Research Group perspective on federal triplicate prescription requirements for controlled substance prescription drugs. NIDA Res Monogr 1993;131:270-8.
3. Eadie JL. New York State's Triplicate Prescription Program. NIDA Res Monogr 1993;131:176-93.
4. Dahl JL, Bennett ME, Bromley MD, Joranson DE. Success of the state pain initiatives: Moving pain management forward. Cancer Pract 2002;10(suppl 1):S9-13.
5. Portenoy RK. The effect of drug regulation on the management of cancer pain. N Y State J Med 1991;91(11 suppl):13S-18S.
6. Fleming DA. Relieving pain: What are today's ethical and legal risks? Mo Med 2002;99:560-5.
7. Pain: The 5th vital sign. Veterans' Healthy Living 2001;Winter:2.
8. Joint Commission on Accreditation of Healthcare Organizations. Pain assessment and management standards - health care networks. JCAHO Requirement. Oakbrook Terrace, IL: Joint Commission Resources; 2001. http://www.jcrinc.com/subscribers/ perspectives.asp?durki=3242&site=10&return=2897.
9. California. Assembly Bill No. 487; 2001.
10. California. Assembly Bill No. 791; 1999.
11. State medical licensure requirements and statistics, 2003: Continuing medical education for licensure reregistration. Chicago, IL: American Medical Association; 2003.
12. Congress US. H.R. 3244, Title VI, Sec. 1603.
13. Lippe PM. The decade of pain control and research. Pain Med 2000;1:286.
14. Gallagher RM. The pain decade and the public health. Pain Med 2000;1:283-5.
15. American Academy of Pain Medicine. The use of opioids for the treatment of chronic pain. Glenview, IL: AAPM; 2003. http://www.painmed.org/productpub/statements/opioidstmt.html.
16. The Federation of State Medical Boards of the United States, Inc. Model guidelines for the use of controlled substances for the treatment of pain.
17. Gilson AM, Joranson DE. U.S. policies relevant to the prescribing of opioid analgesics for the treatment of pain in patients with addictive disease. Clin J Pain 2002;18(4 suppl):S91-8.
18. Adams EH. Prevalence of prescription drug abuse: Data from the National Institute on Drug Abuse. N Y State J Med 1991;91(11 suppl):32S-36S.
19. Simoni-Wastila L, Tompkins C. Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential. Subst Use Misuse 2001;36:1275-96.
20. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000;283:1710-14.
21. Gilson AM, Ryan KM, Joranson DE, Dahl JL. An assessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004;in press.
22. Clark HW. Policy and medical-legal issues in the prescribing of controlled substances. J Psychoactive Drugs 1991;23:321-8.
23. Blum RS. Triplicate prescription forms: Regulatory considerations. Hosp Pract (Off Ed) 1990;25(suppl 3):35-44; discussion 45-6.
24. Fujimoto D. Regulatory issues in pain management. Clin Geriatr Med 2001;17:537-51, vii.
25. Kasprak J. State programs for electronic monitoring of controlled substance prescriptions. Connecticut General Assembly OLR Research Report, Hartford, CT, 2003.
26. Alliance of States with Prescription Monitoring Programs. The goals of prescription monitoring. Quincy, MA: National Association of State Controlled Substances Authorities; 1999. http://www.nascsa.org/alliance/Goals.PDF.
27. Joranson DE, Carrow GM, Ryan KM, Schaefer L, Gilson AM, Good P, Eadie J, Peine S, Dahl JL. Pain management and prescription monitoring. J Pain Symptom Manage 2002;23:231-8.
28. Weissman MM, Johnson J. Drug use and abuse in five US communities. N Y State J Med. 1991;91 (11 suppl):19S-23S.
29. States with prescription monitoring programs. Madison, WI: Pain & Policy Studies Group, University of Wisconsin Comprehensive Cancer Center; 2003. http://www.medsch.wisc.edu/painpolicy/domestic/ PMP_matrix.pdf.
30. American Alliance of Cancer Pain Initiatives urges caution in implementing state prescription monitoring programs: Efforts to curb abuse and diversion of pain medications could adversely affect patient care. Madison, WI: The American Alliance of Cancer Pain Initiatives; Statement on State Prescription Monitoring Programs. The American Alliance of Cancer Pain Initiatives. Medison, WI, 2002. http://www.aacpi.org/regulatory/pmp.pdf
31. Harold Rogers Prescription Drug Monitoring Program. Washington, DC: Bureau of Justice Assistance; 2002. http://www.ojp.usdoj.gov/BJA/grant/prescripdrugs.html.
32. Cope D. States cautioned when developing prescription monitoring programs. Clin J Oncol Nurs 2003;7:19.
33. The American Alliance of Cancer Pain Initiatives statement on state prescription monitoring programs. Madison, WI: The American Alliance of Cancer Pain Initiatives; 2002. http://www.aacpi.org/regulatory/regulatory.html.
34. Collins TM, Zimmerman DR. Programs for monitoring inappropriate prescribing of controlled drugs: Evaluation and recommendations. Am J Hosp Pharm 1992;49:1765-8.
35. Wastila L, Bishop C. The influence of multiple copy prescription on analgesic utilization. J Pharm Care Pain Symptom Control 1996;4:5-19.
36. Berner R. The patient's perspective. N Y State J Med 1991;91(11 suppl):37S-39S.
37. Farnsworth PB. Triplicate prescription: Issues and answers. Introduction. N Y State J Med 1991;91 (11 suppl): 1S-4S.
38. Uzych L. Benzodiazepines and triplicate prescriptions: New York's experience. Tex Med 1991; 87:6.
39. Gil G. Prescription-monitoring system has gaps: Few neighboring states operate similar programs. Louisville, KY: The Courier-Journal; 2002. http://www.courier-journal.com/localnews/2002/10/21/ke102102s299005.htm.
40. Gilson AM, Joranson DE. Controlled substances and pain management: Changes in knowledge and attitudes of state medical regulators. J Pain Symptom Manage 2001;21:227-37.
41. Potter M, Schafer S, Gonzalez-Mendez E, Gjeltema K, Lopez A, Wu J, Pedrin R, Cozen M, Wilson R, Thom D, Croughan-Minihane M. Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. J Fam Pract 2001;50:145-51.
42. Joranson DE, Gilson AM, Dahl JL, Haddox JD. Pain management, controlled substances, and state medical board policy: A decade of change. J Pain Symptom Manage 2002;23:138-47.
43. Weissman DE, Joranson DE, Hopwood MB. Wisconsin physicians' knowledge and attitudes about opioid analgesic regulations. Wis Med J 1991;90:671-5.
44. Turk DC, Brody MC. What position do APSs physician members take on chronic opioid therapy? APS Bull 1992;2:1-5.
45. Sigler KA, Guernsey BG, Ingrim NB, Buesing AS, Hokanson JA, Galvan E, Doutre WH. Effect of a triplicate prescription law on prescribing of Schedule II drugs. Am J Hosp Pharm 1984;41:108-11.
46. Weintraub M, Singh S, Byrne L, Maharaj K, Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991;266:2392-7.
47. Angarola R, Joranson D. State controlled substances laws and pain control. APS Bull 1992;2:10-15.
48. Reidenberg MM. Effect of the requirement for triplicate prescriptions for benzodiazepines in New York State. Clin Pharmacol Ther 1991;50:129-31.
49. Schwartz HI. An empirical review of the impact of triplicate prescription of benzodiazepines. Hosp Community Psychiatry 1992;43:382-5.
50. Collins TM. Multiple copy prescription programs and alternative monitoring programs: Cost issues. N Y State J Med 1991;91(11 suppl):28S-31S.
51. Schwartz HI. Negative clinical consequences of triplicate prescription regulation of benzodiazepines. N Y State J Med 1991;91(11 suppl):9S-12S.
52. Schwartz HI, Blank K. Regulation of benzodiazepine prescribing practices: Clinical implications. Gen Hosp Psychiatry 1991;13:219-24.
53. Hoffman RS, Wipfler MG, Maddaloni MA, Weisman RS. Has the New York State triplicate benzodiazepine prescription regulation influenced sedative-hypnotic overdoses? N Y State J Med 1991;91:436-9.
54. Facts regarding California triplicate prescription requirement. Pasadena, CA: The Southern California Cancer Pain Initiative; 2003. http://www.cityofhope.org/sccpi/2003%20Triplicate%20Fact%20Sheet.htm.
55. California. Assembly Bill No. 2693; 1998.
56. Senate Bill 1308. California State Senate; 1999.
57. California. Assembly Bill No. 2018; 2000.
58. Joranson DE, Gilson AM, Ryan KM, Maurer MA, Nischik JA, Nelson JM. Achieving balance in federal and state pain policy: A guide to evaluation. Madison, WI: Pain & Policy Studies Group, University of Wisconsin Comprehensive Cancer Center; 2000.
59. Senate Bill 151. California State Senate; 2003.
60. Brushwood DB. Maximizing the value of electronic prescription monitoring programs. J Law Med Ethics 2003;31:41-54.
61. Office of Diversion Control. Washington, DC: U.S. Department of Justice Drug Enforcement Administration Diversion Control Program; 2003. http://www.deadiversion.usdoj.gov/.
62. Prescription Accountability Resource Guide -Revised. Washington, DC: U.S. Department of Justice Drug Enforcement Administration Diversion Control Program; 1998. http://www.deadiversion.usdoj.gov/.
63. California Association for Health Services at Home; 2002. http://www.cahsah.org/02Billwatch/sthomecare1005.htm.
64. Provider Support - Counterfeit-Proof Prescription Blank Program. Tallahassee, FL: Florida Medicaid; 2003. http://floridamedicaid.acs-inc.com/index.jsp.
65. The 2002 Florida Statutes. Tallahassee, FL: The Florida Senate; 2002. http://www.flsenate.gov/Statutes/ index.cfm?App_mode=Display_Statute&Search_String=&URL=Ch0409/ SEC912.HTM&Title=→2002→Ch0409→Section%20912.
66. Wiley LF. Florida legislature debates prescription tracking program. St Louis, MO: Pain & The Law; 2003. http://www.painandthelaw.org/entitlements/wiley_040103b.php.
67. Robeznieks A. Prescription monitoring on tap in Florida: Legislation supported by the Florida Medical Assn. and the governor would be implemented with financial support from Purdue Pharma. Chicago: amednews.com; 2003. http://www.amednews.com/2003/prsa0407.
68. Wiley LF. Florida legislature sets prescription tracking program aside. St. Louis, MO: Pain & The Law; 2003. http://www.painandthelaw.org/palliative/wiley_051203.php.
69. Requirements for prescription form (2001). Boise, ID: Idaho State Board of Pharmacy; 2001. http://www.state.id.us/bop.about/rule.470.pdf
70. A closer look at state prescription monitoring programs. Washington, DC: U.S. Department of Justice Drug Enforcement Administration Diversion Control Program; 2000. http://www.deadiversion. usdoj.gov/pubs/program/rx_monitor/index.html.
71. Indiana pharmacy laws and regulations: A compilation of Indiana code and Indiana administrative code. Indianapolis, IN: Indiana Board of Pharmacy & the Indiana Health Professions Bureau; 2002. http://www.in.gov/hpb/boards/isbp/2002_lawbook_complete.PDF.
72. Lackey C. Not what the doctor ordered. State Trends 2001;7:1-3.
73. United States General Accounting Office. Prescription drugs: State monitoring programs provide useful tool to reduce diversion. Washington, DC: U.S. GAO; 2002.
74. Controlled substance prescription blanks. Frankfort, KY. Kentucky Legislature; 1998. http://www.lrc.state.ky.us/kar/902/055/105.htm.
75. Maine Drug Enforcement Agency. Requirements for written prescriptions of schedule II drugs. In: Safety Department of Public Safety, ed. Portland, ME: Maine Drug Enforcement Agency; 2002.
76. Hench D. State to require tamper-resistant forms for prescribing certain narcotic drugs. Portland, ME: Portland Press Herald; 2002:1A.
77. Michigan. House Bills 5260-5262 (As Passed the House): Analysis. Official Prescription Program; 2001.
78. Angarola R, Joranson D. Wins and losses in pain control. APS Bull 1993;3:8-9.
79. Wagenknecht LD. Michigan's triplicate prescription program now in effect. Mich Med 1989;88:32-3.
80. Wasserman S. The double life of OxyContin: Miracle painkiller AND illicit street drug. What are states doing? Denver, CO: National Conference of State Legislatures; 2002. http://www.ncsl.org/programs/health/oxycontin.htm.
81. Michigan automated prescription system. Lansing, MI: Consumer & Industry Services of Michigan; 2003. http://www.michigan.gov/mdch/0,1607,7-132-2747_27648-58273--,00.htm.
82. Public Sector Consultants, Inc. Forgery-resistant prescription paper. Lansing, MI: Michigan Department of Consumer and Industry Services, Bureau of Health Services; 2002.
83. Board of Pharmacy Statutes and Regulations. Newark, NJ: New Jersey Department of Law and Public Safety, Division of Consumer Affairs; 2002. http://www.state.nj.us/lps/ca/pharm/pharmacy.pdf.
84. Farnsworth PB. Triplicate prescription in New York: History and review. N Y State J Med 1991;91(11 suppl):5S-8S.
85. Musto DF. The American disease: Origins of narcotic control. 3rd edition. New York: Oxford University Press; 1999.
86. New York state's new controlled substance law. WhatCity?: New York State Department of Health; 2002. http://www.health.state.ny.us/nysdoh/narcotics.
87. Gage TW. Drug substitution and triplicate prescription forms. Tex Dent J 1982;99:16-7.
88. Berina LF, Guernsey BG, Hokanson JA, Doutre WH, Fuller LE. Physician perception of a triplicate prescription law. Am J Hosp Pharm 1985;42:857-9.
89. Robinson D. Prescribing Controlled Substances for Cancer Pain: Position Paper of the Utah Division of Occupational and Professional Licensing. J Pharm Care Pain Symptom Manage 1993;1:109-112.
90. Wyoming State Board of Pharmacy. Prescription drug monitoring program, 2004. Casper, WY: Wyoming State Board of Pharmacy; 2004. http://pharmacyboard.state.wy.us/pdmp.asp.
91. Trend in state prescription monitoring programs, 1988-2003. Madison, WI: Pain & Policy Studies Group, University of Wisconsin Comprehensive Cancer Center; 2003. http://www.medsch.wisc.edu/painpolicy/domestic/diversion.htm#Trend